Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim's Jascayd (nerandomilast) for the treatment of idiopathic pulmonary fibrosis (IPF), marking the first new therapy for this rare lung disease in more than 10 years. This approval represents a significant milestone in the field of respiratory medicine and offers new hope for patients suffering from this progressive and often fatal condition.
Sanofi, the French pharmaceutical giant, has taken a significant step forward in its artificial intelligence (AI) strategy by partnering with Canadian software company BenchSci. The collaboration, announced on October 8, 2025, aims to integrate AI technology into Sanofi's preclinical research and development processes.
Digital health funding in 2025 is outpacing last year's figures, with a notable increase in large investment rounds and a focus on artificial intelligence-driven healthcare solutions. According to a recent report by Rock Health, U.S. digital health startups have raised $9.9 billion through the third quarter, already surpassing the $8.4 billion raised in the same period last year.
UK-based precision diagnostics company Oxford BioDynamics has made significant progress in developing a first-of-its-kind blood test for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis. The test, which leverages the company's EpiSwitch 3D genomics platform, has shown promising results in a recent study, potentially offering a definitive and timely diagnostic tool for a condition that has long lacked reliable testing methods.
Owens & Minor, a prominent player in the healthcare supply chain, has announced a significant strategic shift with the sale of its healthcare provider supply unit to investment firm Platinum Equity for $375 million. The deal, expected to close by the end of 2025, marks a pivotal moment for Owens & Minor as it refocuses its efforts on its patient direct business.
Arthrosi Therapeutics, a San Diego-based biotech company, has successfully raised $153 million in a Series E financing round to advance its gout treatment candidate, pozdeutinurad. This substantial investment positions the company to deliver data from two pivotal phase 3 trials in 2026, marking a significant milestone in the development of novel therapies for gout.
Eli Lilly's direct-to-consumer care site, LillyDirect, has taken a significant step forward in its evolution by partnering with HealthTap, a virtual primary care provider. This collaboration marks a pivotal moment in the pharmaceutical industry's approach to patient care and medication access.
CSL, the Australian pharmaceutical giant, is pressing forward with its ambitious restructuring plan, aiming to save over $500 million annually in the next three years. This initiative has now reached Vifor Pharma, its Swiss subsidiary, resulting in significant job cuts at the company's U.S. operations.
TransCode Therapeutics, a biotechnology company facing financial uncertainty, has announced two significant deals that promise to reshape its future. The company has acquired Polynoma and its phase 3 cancer vaccine while simultaneously securing a $25 million investment, albeit at the cost of substantial equity dilution.
In a significant development for the pharmacy benefit manager (PBM) industry, Adam Kautzner, president of Express Scripts, has been appointed as the new board chair of the Pharmaceutical Care Management Association (PCMA). This move comes at a time when PBMs are under increasing scrutiny for their role in rising drug costs and market concentration.
Xspray Pharma has encountered another setback in its efforts to bring its leukemia drug Dasynoc to market, as the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) rejecting the company's latest approval bid. This marks the third such rejection in as many years, further delaying the potential launch of the drug intended to compete with Bristol Myers Squibb's blockbuster Sprycel.
The Advanced Research Projects Agency for Health (ARPA-H) has unveiled its latest round of grant awardees for the Engineering of Immune Cells Inside the Body (EMBODY) program, signaling a significant shift in federal research funding priorities. This move highlights the second Trump administration's focus on advancing in vivo cell therapies, particularly in the realms of cancer treatment and autoimmune disorders.
